Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

Exclusion Criteria

• •Kidney or other solid organ or bone marrow transplant recipient
• •Allergy or intolerance to investigational agent
• •Secondary Focal Segmental Glomerulosclerosis (FSGS)
• •Severe obesity
• •Live virus vaccine in the past 3 months
• •Malignancy, current or in the past 5 years
• •Active local or systemic bacterial, fungal or viral infection
• •Active or latent Hepatitis B, Hepatitis C, HIV, or tuberculosis
• •History of demyelinating disease, e.g. Multiple Sclerosis or Guillain-Barre
• •History of heart failure
• •Active liver disease
• •Systemic lupus erythematosus or ANA \> 1:80
• •History of inflammatory bowel disease, e.g. ulcerative colitis or Crohns disease
• •Cyclophosphamide in past 90 days, Rituximab in the past 180 days
• •Pregnancy or nursing
• •Blood white blood cell count \<4,500/mm3; Hg \<9 g/dL; Platelet count \<150,000/mm3 at enrollment. - Use of an erythropoiesis stimulating agent will not be an exclusion criterion.
• •Concurrent use of interleukin-1 antagonist (Anakinra), other TNF blocking agent, methotrexate or abatacept
• •Diabetes Mellitus